The global Anti-IL-4Rα Antibody market was valued at US$ 17694 million in 2025 and is anticipated to reach US$ 37139 million by 2032, at a CAGR of 11.4% from 2026 to 2032.

Anti-IL-4Rα Antibody Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Anti-IL-4Rα Antibody competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global Anti-IL-4Rα Antibody production reached approximately 61.92 M Units, with an average global market price of around 285 USD per Unit.

An anti-IL-4Rα antibody is a monoclonal antibody designed to bind the interleukin-4 receptor alpha subunit (IL-4Rα), a shared receptor component used by IL-4 and IL-13 signaling pathways. By blocking IL-4Rα, these antibodies inhibit Type-2 (Th2) inflammation, reducing downstream allergic and eosinophilic immune responses, and are used or developed to treat Type-2 inflammatory diseases such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and related conditions.

Anti-IL-4Rα antibodies have become a flagship modality in immunology because they address a persistent industry pain point in Type-2 inflammation: many patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and related conditions remain symptomatic or dependent on corticosteroids despite conventional therapies, and they often cycle between organ-specific treatments that don’t control the shared upstream biology. By blocking IL-4Rα—the common signaling node for IL-4 and IL-13—this class offers a mechanism-based, “upstream” approach that can reduce inflammation across multiple tissues with a single targeted therapy, supporting durable disease control while potentially lowering steroid burden and improving quality of life in a way that is operationally feasible for long-term use. The market potential remains strong as Type-2 inflammatory diseases continue to be diagnosed earlier and treated more proactively, as new entrants compete on convenience, access, and tailored positioning in specific phenotypes, and as the pathway’s central role enables expansion into additional indications where IL-4/IL-13 signaling is clinically meaningful, sustaining a large and resilient opportunity.

The upstream raw materials for anti-IL-4Rα antibody mainly include core biological materials such as recombinant IL-4Rα antigen, engineered cell lines, and plasmids/vectors. Typical raw material suppliers include Thermo Fisher, Bio-Techne (Novus), Cytiva, Merck Millipore, etc. The downstream applications are mainly in the treatment of allergic dermatitis and respiratory diseases.

The production capacity of single-line anti-IL-4Rα antibody varies greatly depending on the type of drug molecule, process complexity, equipment scale and production mode, and the industry gross profit margin is usually in the range of 60%-80%.

The North American market for Anti-IL-4Rα Antibody is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Anti-IL-4Rα Antibody is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of Anti-IL-4Rα Antibody include Sanofi, Connect Biopharma, Keymed Biosciences, Jiangsu Simcere Pharmaceutical, Genrix Bio, Jiangsu Quan Xin Biomedical, Jiangsu Hengrui Medicine, Akeso Biopharma, Mabgeek Biotechnology, Chia Tai-Tianqing Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Anti-IL-4Rα Antibody market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-IL-4Rα Antibody. The Anti-IL-4Rα Antibody market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Anti-IL-4Rα Antibody market comprehensively. Regional market sizes by Type, by Application, by Action Mechanism, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Anti-IL-4Rα Antibody manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Anti-IL-4Rα Antibody Market Report

Report Metric	Details
Report Name	Anti-IL-4Rα Antibody Market
Accounted market size in 2025	US$ 17694 million
Forecasted market size in 2032	US$ 37139 million
CAGR	11.4%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Subcutaneous Injection Inhalation Preparations Others
Segment by Action Mechanism	Competitive Blockade Allosteric Regulation Receptor Degradation Others
Segment by Molecular Form	Monospecific Antibodies Bispecific Antibodies Others
by Application	Allergic Dermatitis Respiratory Diseases Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi, Connect Biopharma, Keymed Biosciences, Jiangsu Simcere Pharmaceutical, Genrix Bio, Jiangsu Quan Xin Biomedical, Jiangsu Hengrui Medicine, Akeso Biopharma, Mabgeek Biotechnology, Chia Tai-Tianqing Pharmaceutical, Boan Biotechnology, Novamab
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Action Mechanism, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Anti-IL-4Rα Antibody manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Anti-IL-4Rα Antibody sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Anti-IL-4Rα Antibody Market growing?

Ans: The Anti-IL-4Rα Antibody Market witnessing a CAGR of 11.4% during the forecast period 2026-2032.

What is the Anti-IL-4Rα Antibody Market size in 2032?

Ans: The Anti-IL-4Rα Antibody Market size in 2032 will be US$ 37139 million.

Who are the main players in the Anti-IL-4Rα Antibody Market report?

Ans: The main players in the Anti-IL-4Rα Antibody Market are Sanofi, Connect Biopharma, Keymed Biosciences, Jiangsu Simcere Pharmaceutical, Genrix Bio, Jiangsu Quan Xin Biomedical, Jiangsu Hengrui Medicine, Akeso Biopharma, Mabgeek Biotechnology, Chia Tai-Tianqing Pharmaceutical, Boan Biotechnology, Novamab

What are the Application segmentation covered in the Anti-IL-4Rα Antibody Market report?

Ans: The Applications covered in the Anti-IL-4Rα Antibody Market report are Allergic Dermatitis, Respiratory Diseases, Others

What are the Type segmentation covered in the Anti-IL-4Rα Antibody Market report?

Ans: The Types covered in the Anti-IL-4Rα Antibody Market report are Subcutaneous Injection, Inhalation Preparations, Others

1 Anti-IL-4Rα Antibody Market Overview

1.1 Product Definition

1.2 Anti-IL-4Rα Antibody by Type

1.2.1 Global Anti-IL-4Rα Antibody Market Value by Type: 2025 vs 2032

1.2.2 Subcutaneous Injection

1.2.3 Inhalation Preparations

1.2.4 Others

1.3 Anti-IL-4Rα Antibody by Action Mechanism

1.3.1 Global Anti-IL-4Rα Antibody Market Value by Action Mechanism: 2025 vs 2032

1.3.2 Competitive Blockade

1.3.3 Allosteric Regulation

1.3.4 Receptor Degradation

1.3.5 Others

1.4 Anti-IL-4Rα Antibody by Molecular Form

1.4.1 Global Anti-IL-4Rα Antibody Market Value by Molecular Form: 2025 vs 2032

1.4.2 Monospecific Antibodies

1.4.3 Bispecific Antibodies

1.4.4 Others

1.5 Anti-IL-4Rα Antibody by Application

1.5.1 Global Anti-IL-4Rα Antibody Market Value by Application: 2025 vs 2032

1.5.2 Allergic Dermatitis

1.5.3 Respiratory Diseases

1.5.4 Others

1.6 Global Anti-IL-4Rα Antibody Market Size Estimates and Forecasts

1.6.1 Global Anti-IL-4Rα Antibody Revenue 2021–2032

1.6.2 Global Anti-IL-4Rα Antibody Sales 2021–2032

1.6.3 Global Anti-IL-4Rα Antibody Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Anti-IL-4Rα Antibody Market Competition by Manufacturers

2.1 Global Anti-IL-4Rα Antibody Sales Market Share by Manufacturers (2021–2026)

2.2 Global Anti-IL-4Rα Antibody Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Anti-IL-4Rα Antibody Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Anti-IL-4Rα Antibody, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Anti-IL-4Rα Antibody, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Anti-IL-4Rα Antibody, Product Types and Applications

2.7 Global Key Manufacturers of Anti-IL-4Rα Antibody, Date of Entry into the Industry

2.8 Global Anti-IL-4Rα Antibody Market Competitive Situation and Trends

2.8.1 Global Anti-IL-4Rα Antibody Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Anti-IL-4Rα Antibody Players Market Share by Revenue

2.8.3 Global Anti-IL-4Rα Antibody Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Anti-IL-4Rα Antibody Market Scenario by Region

3.1 Global Anti-IL-4Rα Antibody Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Anti-IL-4Rα Antibody Sales by Region: 2021–2032

3.2.1 Global Anti-IL-4Rα Antibody Sales by Region: 2021–2026

3.2.2 Global Anti-IL-4Rα Antibody Sales by Region: 2027–2032

3.3 Global Anti-IL-4Rα Antibody Revenue by Region: 2021–2032

3.3.1 Global Anti-IL-4Rα Antibody Revenue by Region: 2021–2026

3.3.2 Global Anti-IL-4Rα Antibody Revenue by Region: 2027–2032

3.4 North America Anti-IL-4Rα Antibody Market Facts & Figures by Country

3.4.1 North America Anti-IL-4Rα Antibody Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Anti-IL-4Rα Antibody Sales by Country (2021–2032)

3.4.3 North America Anti-IL-4Rα Antibody Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Anti-IL-4Rα Antibody Market Facts & Figures by Country

3.5.1 Europe Anti-IL-4Rα Antibody Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Anti-IL-4Rα Antibody Sales by Country (2021–2032)

3.5.3 Europe Anti-IL-4Rα Antibody Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Anti-IL-4Rα Antibody Market Facts & Figures by Region

3.6.1 Asia Pacific Anti-IL-4Rα Antibody Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Anti-IL-4Rα Antibody Sales by Region (2021–2032)

3.6.3 Asia Pacific Anti-IL-4Rα Antibody Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Anti-IL-4Rα Antibody Market Facts & Figures by Country

3.7.1 Latin America Anti-IL-4Rα Antibody Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Anti-IL-4Rα Antibody Sales by Country (2021–2032)

3.7.3 Latin America Anti-IL-4Rα Antibody Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Anti-IL-4Rα Antibody Market Facts & Figures by Country

3.8.1 Middle East and Africa Anti-IL-4Rα Antibody Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Anti-IL-4Rα Antibody Sales by Country (2021–2032)

3.8.3 Middle East and Africa Anti-IL-4Rα Antibody Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Anti-IL-4Rα Antibody Sales by Type (2021–2032)

4.1.1 Global Anti-IL-4Rα Antibody Sales by Type (2021–2026)

4.1.2 Global Anti-IL-4Rα Antibody Sales by Type (2027–2032)

4.1.3 Global Anti-IL-4Rα Antibody Sales Market Share by Type (2021–2032)

4.2 Global Anti-IL-4Rα Antibody Revenue by Type (2021–2032)

4.2.1 Global Anti-IL-4Rα Antibody Revenue by Type (2021–2026)

4.2.2 Global Anti-IL-4Rα Antibody Revenue by Type (2027–2032)

4.2.3 Global Anti-IL-4Rα Antibody Revenue Market Share by Type (2021–2032)

4.3 Global Anti-IL-4Rα Antibody Price by Type (2021–2032)

5 Segment by Application

5.1 Global Anti-IL-4Rα Antibody Sales by Application (2021–2032)

5.1.1 Global Anti-IL-4Rα Antibody Sales by Application (2021–2026)

5.1.2 Global Anti-IL-4Rα Antibody Sales by Application (2027–2032)

5.1.3 Global Anti-IL-4Rα Antibody Sales Market Share by Application (2021–2032)

5.2 Global Anti-IL-4Rα Antibody Revenue by Application (2021–2032)

5.2.1 Global Anti-IL-4Rα Antibody Revenue by Application (2021–2026)

5.2.2 Global Anti-IL-4Rα Antibody Revenue by Application (2027–2032)

5.2.3 Global Anti-IL-4Rα Antibody Revenue Market Share by Application (2021–2032)

5.3 Global Anti-IL-4Rα Antibody Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Sanofi

6.1.1 Sanofi Company Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Sanofi Anti-IL-4Rα Antibody Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 Connect Biopharma

6.2.1 Connect Biopharma Company Information

6.2.2 Connect Biopharma Description and Business Overview

6.2.3 Connect Biopharma Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Connect Biopharma Anti-IL-4Rα Antibody Product Portfolio

6.2.5 Connect Biopharma Recent Developments/Updates

6.3 Keymed Biosciences

6.3.1 Keymed Biosciences Company Information

6.3.2 Keymed Biosciences Description and Business Overview

6.3.3 Keymed Biosciences Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Keymed Biosciences Anti-IL-4Rα Antibody Product Portfolio

6.3.5 Keymed Biosciences Recent Developments/Updates

6.4 Jiangsu Simcere Pharmaceutical

6.4.1 Jiangsu Simcere Pharmaceutical Company Information

6.4.2 Jiangsu Simcere Pharmaceutical Description and Business Overview

6.4.3 Jiangsu Simcere Pharmaceutical Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Jiangsu Simcere Pharmaceutical Anti-IL-4Rα Antibody Product Portfolio

6.4.5 Jiangsu Simcere Pharmaceutical Recent Developments/Updates

6.5 Genrix Bio

6.5.1 Genrix Bio Company Information

6.5.2 Genrix Bio Description and Business Overview

6.5.3 Genrix Bio Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Genrix Bio Anti-IL-4Rα Antibody Product Portfolio

6.5.5 Genrix Bio Recent Developments/Updates

6.6 Jiangsu Quan Xin Biomedical

6.6.1 Jiangsu Quan Xin Biomedical Company Information

6.6.2 Jiangsu Quan Xin Biomedical Description and Business Overview

6.6.3 Jiangsu Quan Xin Biomedical Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Jiangsu Quan Xin Biomedical Anti-IL-4Rα Antibody Product Portfolio

6.6.5 Jiangsu Quan Xin Biomedical Recent Developments/Updates

6.7 Jiangsu Hengrui Medicine

6.7.1 Jiangsu Hengrui Medicine Company Information

6.7.2 Jiangsu Hengrui Medicine Description and Business Overview

6.7.3 Jiangsu Hengrui Medicine Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Jiangsu Hengrui Medicine Anti-IL-4Rα Antibody Product Portfolio

6.7.5 Jiangsu Hengrui Medicine Recent Developments/Updates

6.8 Akeso Biopharma

6.8.1 Akeso Biopharma Company Information

6.8.2 Akeso Biopharma Description and Business Overview

6.8.3 Akeso Biopharma Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Akeso Biopharma Anti-IL-4Rα Antibody Product Portfolio

6.8.5 Akeso Biopharma Recent Developments/Updates

6.9 Mabgeek Biotechnology

6.9.1 Mabgeek Biotechnology Company Information

6.9.2 Mabgeek Biotechnology Description and Business Overview

6.9.3 Mabgeek Biotechnology Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Mabgeek Biotechnology Anti-IL-4Rα Antibody Product Portfolio

6.9.5 Mabgeek Biotechnology Recent Developments/Updates

6.10 Chia Tai-Tianqing Pharmaceutical

6.10.1 Chia Tai-Tianqing Pharmaceutical Company Information

6.10.2 Chia Tai-Tianqing Pharmaceutical Description and Business Overview

6.10.3 Chia Tai-Tianqing Pharmaceutical Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Chia Tai-Tianqing Pharmaceutical Anti-IL-4Rα Antibody Product Portfolio

6.10.5 Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates

6.11 Boan Biotechnology

6.11.1 Boan Biotechnology Company Information

6.11.2 Boan Biotechnology Description and Business Overview

6.11.3 Boan Biotechnology Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Boan Biotechnology Anti-IL-4Rα Antibody Product Portfolio

6.11.5 Boan Biotechnology Recent Developments/Updates

6.12 Novamab

6.12.1 Novamab Company Information

6.12.2 Novamab Description and Business Overview

6.12.3 Novamab Anti-IL-4Rα Antibody Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 Novamab Anti-IL-4Rα Antibody Product Portfolio

6.12.5 Novamab Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Anti-IL-4Rα Antibody Industry Chain Analysis

7.2 Anti-IL-4Rα Antibody Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Anti-IL-4Rα Antibody Production Mode & Process Analysis

7.4 Anti-IL-4Rα Antibody Sales and Marketing

7.4.1 Anti-IL-4Rα Antibody Sales Channels

7.4.2 Anti-IL-4Rα Antibody Distributors

7.5 Anti-IL-4Rα Antibody Customer Analysis

8 Anti-IL-4Rα Antibody Market Dynamics

8.1 Anti-IL-4Rα Antibody Industry Trends

8.2 Anti-IL-4Rα Antibody Market Drivers

8.3 Anti-IL-4Rα Antibody Market Challenges

8.4 Anti-IL-4Rα Antibody Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi

KeyMed Biosciences

Jiangsu Simcere Pharmaceutical

Genrix Bio

Jiangsu Hengrui Medicine

Akeso Biopharma

Chia Tai-Tianqing Pharmaceutical

Novamab

Connect Biopharma

Jiangsu Quan Xin Biomedical

Mabgeek Biotechnology

Boan Biotechnology

List of Tables

Table 1. Global Anti-IL-4Rα Antibody Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Anti-IL-4Rα Antibody Market Value by Action Mechanism (US$ Million), 2025 vs 2032

Table 3. Global Anti-IL-4Rα Antibody Market Value by Molecular Form (US$ Million), 2025 vs 2032

Table 4. Global Anti-IL-4Rα Antibody Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Anti-IL-4Rα Antibody Market Competitive Situation by Manufacturers in 2025

Table 6. Global Anti-IL-4Rα Antibody Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global Anti-IL-4Rα Antibody Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Anti-IL-4Rα Antibody Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Anti-IL-4Rα Antibody Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Anti-IL-4Rα Antibody Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Anti-IL-4Rα Antibody, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Anti-IL-4Rα Antibody, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Anti-IL-4Rα Antibody, Product Types and Applications

Table 14. Global Key Manufacturers of Anti-IL-4Rα Antibody, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Anti-IL-4Rα Antibody Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-IL-4Rα Antibody Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Anti-IL-4Rα Antibody Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Anti-IL-4Rα Antibody Sales by Region (K Units), 2021–2026

Table 20. Global Anti-IL-4Rα Antibody Sales Market Share by Region (2021–2026)

Table 21. Global Anti-IL-4Rα Antibody Sales by Region (K Units), 2027–2032

Table 22. Global Anti-IL-4Rα Antibody Sales Market Share by Region (2027–2032)

Table 23. Global Anti-IL-4Rα Antibody Revenue by Region (US$ Million), 2021–2026

Table 24. Global Anti-IL-4Rα Antibody Revenue Market Share by Region (2021–2026)

Table 25. Global Anti-IL-4Rα Antibody Revenue by Region (US$ Million), 2027–2032

Table 26. Global Anti-IL-4Rα Antibody Revenue Market Share by Region (2027–2032)

Table 27. North America Anti-IL-4Rα Antibody Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Anti-IL-4Rα Antibody Sales by Country (K Units), 2021–2026

Table 29. North America Anti-IL-4Rα Antibody Sales by Country (K Units), 2027–2032

Table 30. North America Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2021–2026

Table 31. North America Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Anti-IL-4Rα Antibody Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Anti-IL-4Rα Antibody Sales by Country (K Units), 2021–2026

Table 34. Europe Anti-IL-4Rα Antibody Sales by Country (K Units), 2027–2032

Table 35. Europe Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Anti-IL-4Rα Antibody Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Anti-IL-4Rα Antibody Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific Anti-IL-4Rα Antibody Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific Anti-IL-4Rα Antibody Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Anti-IL-4Rα Antibody Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Anti-IL-4Rα Antibody Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Anti-IL-4Rα Antibody Sales by Country (K Units), 2021–2026

Table 44. Latin America Anti-IL-4Rα Antibody Sales by Country (K Units), 2027–2032

Table 45. Latin America Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Anti-IL-4Rα Antibody Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Anti-IL-4Rα Antibody Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa Anti-IL-4Rα Antibody Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Anti-IL-4Rα Antibody Revenue by Country (US$ Million), 2027–2032

Table 52. Global Anti-IL-4Rα Antibody Sales (K Units) by Type (2021–2026)

Table 53. Global Anti-IL-4Rα Antibody Sales (K Units) by Type (2027–2032)

Table 54. Global Anti-IL-4Rα Antibody Sales Market Share by Type (2021–2026)

Table 55. Global Anti-IL-4Rα Antibody Sales Market Share by Type (2027–2032)

Table 56. Global Anti-IL-4Rα Antibody Revenue (US$ Million) by Type (2021–2026)

Table 57. Global Anti-IL-4Rα Antibody Revenue (US$ Million) by Type (2027–2032)

Table 58. Global Anti-IL-4Rα Antibody Revenue Market Share by Type (2021–2026)

Table 59. Global Anti-IL-4Rα Antibody Revenue Market Share by Type (2027–2032)

Table 60. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Type (2021–2026)

Table 61. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Type (2027–2032)

Table 62. Global Anti-IL-4Rα Antibody Sales (K Units) by Application (2021–2026)

Table 63. Global Anti-IL-4Rα Antibody Sales (K Units) by Application (2027–2032)

Table 64. Global Anti-IL-4Rα Antibody Sales Market Share by Application (2021–2026)

Table 65. Global Anti-IL-4Rα Antibody Sales Market Share by Application (2027–2032)

Table 66. Global Anti-IL-4Rα Antibody Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Anti-IL-4Rα Antibody Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Anti-IL-4Rα Antibody Revenue Market Share by Application (2021–2026)

Table 69. Global Anti-IL-4Rα Antibody Revenue Market Share by Application (2027–2032)

Table 70. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Application (2021–2026)

Table 71. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Application (2027–2032)

Table 72. Sanofi Company Information

Table 73. Sanofi Description and Business Overview

Table 74. Sanofi Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Sanofi Anti-IL-4Rα Antibody Product

Table 76. Sanofi Recent Developments/Updates

Table 77. Connect Biopharma Company Information

Table 78. Connect Biopharma Description and Business Overview

Table 79. Connect Biopharma Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Connect Biopharma Anti-IL-4Rα Antibody Product

Table 81. Connect Biopharma Recent Developments/Updates

Table 82. Keymed Biosciences Company Information

Table 83. Keymed Biosciences Description and Business Overview

Table 84. Keymed Biosciences Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Keymed Biosciences Anti-IL-4Rα Antibody Product

Table 86. Keymed Biosciences Recent Developments/Updates

Table 87. Jiangsu Simcere Pharmaceutical Company Information

Table 88. Jiangsu Simcere Pharmaceutical Description and Business Overview

Table 89. Jiangsu Simcere Pharmaceutical Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. Jiangsu Simcere Pharmaceutical Anti-IL-4Rα Antibody Product

Table 91. Jiangsu Simcere Pharmaceutical Recent Developments/Updates

Table 92. Genrix Bio Company Information

Table 93. Genrix Bio Description and Business Overview

Table 94. Genrix Bio Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Genrix Bio Anti-IL-4Rα Antibody Product

Table 96. Genrix Bio Recent Developments/Updates

Table 97. Jiangsu Quan Xin Biomedical Company Information

Table 98. Jiangsu Quan Xin Biomedical Description and Business Overview

Table 99. Jiangsu Quan Xin Biomedical Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. Jiangsu Quan Xin Biomedical Anti-IL-4Rα Antibody Product

Table 101. Jiangsu Quan Xin Biomedical Recent Developments/Updates

Table 102. Jiangsu Hengrui Medicine Company Information

Table 103. Jiangsu Hengrui Medicine Description and Business Overview

Table 104. Jiangsu Hengrui Medicine Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Jiangsu Hengrui Medicine Anti-IL-4Rα Antibody Product

Table 106. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 107. Akeso Biopharma Company Information

Table 108. Akeso Biopharma Description and Business Overview

Table 109. Akeso Biopharma Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 110. Akeso Biopharma Anti-IL-4Rα Antibody Product

Table 111. Akeso Biopharma Recent Developments/Updates

Table 112. Mabgeek Biotechnology Company Information

Table 113. Mabgeek Biotechnology Description and Business Overview

Table 114. Mabgeek Biotechnology Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 115. Mabgeek Biotechnology Anti-IL-4Rα Antibody Product

Table 116. Mabgeek Biotechnology Recent Developments/Updates

Table 117. Chia Tai-Tianqing Pharmaceutical Company Information

Table 118. Chia Tai-Tianqing Pharmaceutical Description and Business Overview

Table 119. Chia Tai-Tianqing Pharmaceutical Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 120. Chia Tai-Tianqing Pharmaceutical Anti-IL-4Rα Antibody Product

Table 121. Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates

Table 122. Boan Biotechnology Company Information

Table 123. Boan Biotechnology Description and Business Overview

Table 124. Boan Biotechnology Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 125. Boan Biotechnology Anti-IL-4Rα Antibody Product

Table 126. Boan Biotechnology Recent Developments/Updates

Table 127. Novamab Company Information

Table 128. Novamab Description and Business Overview

Table 129. Novamab Anti-IL-4Rα Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 130. Novamab Anti-IL-4Rα Antibody Product

Table 131. Novamab Recent Developments/Updates

Table 132. Key Raw Materials Lists

Table 133. Raw Materials Key Suppliers Lists

Table 134. Anti-IL-4Rα Antibody Distributors List

Table 135. Anti-IL-4Rα Antibody Customers List

Table 136. Anti-IL-4Rα Antibody Market Trends

Table 137. Anti-IL-4Rα Antibody Market Drivers

Table 138. Anti-IL-4Rα Antibody Market Challenges

Table 139. Anti-IL-4Rα Antibody Market Restraints

Table 140. Research Programs/Design for This Report

Table 141. Key Data Information from Secondary Sources

Table 142. Key Data Information from Primary Sources

Table 143. Authors List of This Report

List of Figures

Figure 1. Product Picture of Anti-IL-4Rα Antibody

Figure 2. Global Anti-IL-4Rα Antibody Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Anti-IL-4Rα Antibody Market Share by Type: 2025 & 2032

Figure 4. Subcutaneous Injection Product Picture

Figure 5. Inhalation Preparations Product Picture

Figure 6. Others Product Picture

Figure 7. Global Anti-IL-4Rα Antibody Market Value by Action Mechanism (US$ Million), 2021–2032

Figure 8. Global Anti-IL-4Rα Antibody Market Share by Action Mechanism: 2025 vs 2032

Figure 9. Competitive Blockade Product Picture

Figure 10. Allosteric Regulation Product Picture

Figure 11. Receptor Degradation Product Picture

Figure 12. Others Product Picture

Figure 13. Global Anti-IL-4Rα Antibody Market Value by Molecular Form (US$ Million), 2021–2032

Figure 14. Global Anti-IL-4Rα Antibody Market Share by Molecular Form: 2025 vs 2032

Figure 15. Monospecific Antibodies Product Picture

Figure 16. Bispecific Antibodies Product Picture

Figure 17. Others Product Picture

Figure 18. Global Anti-IL-4Rα Antibody Market Value by Application (US$ Million), 2021–2032

Figure 19. Global Anti-IL-4Rα Antibody Market Share by Application: 2025 & 2032

Figure 20. Allergic Dermatitis

Figure 21. Respiratory Diseases

Figure 22. Others

Figure 23. Global Anti-IL-4Rα Antibody Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 24. Global Anti-IL-4Rα Antibody Market Size (US$ Million), 2021–2032

Figure 25. Global Anti-IL-4Rα Antibody Sales (K Units), 2021–2032

Figure 26. Global Anti-IL-4Rα Antibody Average Price (US$/Unit), 2021–2032

Figure 27. Anti-IL-4Rα Antibody Report Years Considered

Figure 28. Anti-IL-4Rα Antibody Sales Share by Manufacturers in 2025

Figure 29. Global Anti-IL-4Rα Antibody Revenue Share by Manufacturers in 2025

Figure 30. Top 5 and Top 10 Global Anti-IL-4Rα Antibody Players: Market Share by Revenue in Anti-IL-4Rα Antibody in 2025

Figure 31. Anti-IL-4Rα Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 32. Global Anti-IL-4Rα Antibody Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 33. North America Anti-IL-4Rα Antibody Sales Market Share by Country (2021–2032)

Figure 34. North America Anti-IL-4Rα Antibody Revenue Market Share by Country (2021–2032)

Figure 35. United States Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. Canada Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. Europe Anti-IL-4Rα Antibody Sales Market Share by Country (2021–2032)

Figure 38. Europe Anti-IL-4Rα Antibody Revenue Market Share by Country (2021–2032)

Figure 39. Germany Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. France Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. U.K. Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Italy Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Russia Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Asia Pacific Anti-IL-4Rα Antibody Sales Market Share by Region (2021–2032)

Figure 45. Asia Pacific Anti-IL-4Rα Antibody Revenue Market Share by Region (2021–2032)

Figure 46. China Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Japan Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. South Korea Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. India Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Australia Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. China Taiwan Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Southeast Asia Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Latin America Anti-IL-4Rα Antibody Sales Market Share by Country (2021–2032)

Figure 54. Latin America Anti-IL-4Rα Antibody Revenue Market Share by Country (2021–2032)

Figure 55. Mexico Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Brazil Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Argentina Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Colombia Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. Middle East and Africa Anti-IL-4Rα Antibody Sales Market Share by Country (2021–2032)

Figure 60. Middle East and Africa Anti-IL-4Rα Antibody Revenue Market Share by Country (2021–2032)

Figure 61. Turkey Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Saudi Arabia Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 63. UAE Anti-IL-4Rα Antibody Revenue Growth Rate (US$ Million), 2021–2032

Figure 64. Global Sales Market Share of Anti-IL-4Rα Antibody by Type (2021–2032)

Figure 65. Global Revenue Market Share of Anti-IL-4Rα Antibody by Type (2021–2032)

Figure 66. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Type (2021–2032)

Figure 67. Global Sales Market Share of Anti-IL-4Rα Antibody by Application (2021–2032)

Figure 68. Global Revenue Market Share of Anti-IL-4Rα Antibody by Application (2021–2032)

Figure 69. Global Anti-IL-4Rα Antibody Price (US$/Unit) by Application (2021–2032)

Figure 70. Anti-IL-4Rα Antibody Value Chain

Figure 71. Channels of Distribution (Direct Vs Distribution)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions